Please assess the completion status of the following clinical trial:

Trial Title: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent form voluntarily.~* Histologically or cytologically documented hepatocellular carcinoma.~* BCLC stage C, and non-resectable BCLC stage B .~* At least one measurable lesion according to RECIST criteria.~* ECOG of 0 or 1.~* Adequate organ function.~* Estimated life expectancy of ≥3 months.~* For women of childbearing potential: agreement to remain abstinent; For men: agreement to remain abstinent.~Exclusion Criteria:~* Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.~* History of hepatic encephalopathy or liver transplantation.~* Clinical significance of hydrothorax, ascites or pericardial effusion.~* Central nervous system metastases and/or carcinomatous meningitis.~* Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy.~* Occurred arteriovenous thromboembolic events within 6 months before the first administration.~* Tumor volume \> 50% liver volume; portal vein tumor thrombus or inferior vena cava tumor thrombus.~* Inadequately controlled arterial hypertension.~* Attack of symptomatic congestive heart failure (LVEF\<50%); History of congenital long QT syndrome.~* Known presence or history of interstitial lung disease or required hormone treatment interstitial lung disease.~* Severe infections.~* Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy,~* Enrollment of another clinical study within 4 weeks prior to the first administration of study drugs.~* Unable to receive an enhanced CT or MRI scan of the liver.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AK104 and Lenvatinib (Type: EXPERIMENTAL): AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight\<60kg,PO QD

Based on this trial design, predict the completion outcome and termination type (if applicable).